About: http://webisa.webdatacommons.org/19061498

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	If approved, oral tofacitinib would be a strong competitor to biologics such as Enbrel and Humira.
http://www.w3.org/ns/prov#wasQuotedFrom	research-store.com